Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact

Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks.

On February 24, BofA said Novo Nordisk’s determination to chopped GLP-1 database prices whitethorn gully attention, but the steadfast does not expect a meaningful interaction connected the US market. BofA views the determination chiefly arsenic an effort to little copay and coinsurance costs for patients, particularly successful cases wherever those costs are tied to the database oregon WAC price. The steadfast besides said investors are close to ticker however reimbursement trends evolve. Based connected its transmission checks, broader commercialized security sum for GLP-1 drugs whitethorn beryllium connected whether PBM pricing aligns much intimately with user currency prices.

Even so, BofA believes the wide effect connected Eli Lilly and Company (NYSE:LLY)’s GLP-1 concern should stay limited. The steadfast noted determination is nary wide motion that Novo Nordisk is aggressively lowering nett prices successful the commercialized security channel. It besides expects Eli Lilly to payment from increasing request successful cash-pay and U.S. authorities channels, which are not affected by Novo’s latest pricing move. BofA maintained a Buy standing connected Eli Lilly.

On February 23, Eli Lilly announced that the U.S. Food and Drug Administration approved a four-dose KwikPen for its weight-loss cause Zepbound. The caller instrumentality allows patients to person a afloat period of attraction successful a azygous pen. This marks a antithetic attack compared to Novo Nordisk’s Wegovy, which has been offered arsenic a single-dose play autoinjector successful the U.S. since 2021.

Zepbound KwikPen volition beryllium disposable starting astatine $299 per period for the 2.5 mg dose for cash-paying customers. The instrumentality volition beryllium offered successful each six dose levels: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The KwikPen is already acquainted to galore patients. Lilly uses the aforesaid instrumentality to present its diabetes cause Mounjaro. It is besides disposable successful respective large planetary markets, including the United Kingdom, Australia, the Middle East, and Canada.

Zepbound itself received FDA support successful 2023. In the US, it is presently disposable arsenic a single-dose autoinjector oregon successful vial form.

Eli Lilly and Company (NYSE:LLY) operates arsenic a planetary pharmaceutical company. It focuses connected discovering, developing, manufacturing, and selling medicines crossed a wide scope of wellness conditions.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.